Andreasyan, Armen and Mendoza, Luis (2022) Emergent New Anti PD-1/PD-L1 Small Molecules for Cancer Treatment. International Research Journal of Oncology, 6 (1). pp. 18-24.
91-Article Text-145-1-10-20220917.pdf - Published Version
Download (237kB)
Abstract
Currently all approved PD-1/PD-L1 inhibitors are monoclonal antibodies. Along with that, compounds from other chemical classes are being investigated as well. Among those are small molecules which demonstrate commensurable therapeutic effect in preclinical and early clinical development. In comparison with antibodies, small molecules have certain advantages such as shorter blood half-times and possibility for oral intake. If clinical trials will confirm acceptable therapeutic and safety profile in forthcoming years, these agents may become good alternatives to the monoclonal antibodies for using in treatment regimens implementing immune checkpoint inhibition via PD-1/PD-L1 pathway.
Item Type: | Article |
---|---|
Subjects: | European Repository > Medical Science |
Depositing User: | Managing Editor |
Date Deposited: | 12 Jan 2023 06:20 |
Last Modified: | 03 Feb 2024 04:00 |
URI: | http://go7publish.com/id/eprint/1740 |